诺为泰（Novotech）：2024肝癌：全球临床试验概况报告（中译版）（19页）.pdf

1、novotech-MAY 13,2024Liver Cancer-Global Clinical Trial Landscape(2024)Countries like Mainland China,the United States,South Korea,and Spain emerged as top locations for conducting trials.Asia-Pacific showed faster recruitment durations and patient recruit-ment ratesGlobally,liver cancer is the sixth

2、 most diagnosed cancer and the third leading cause of cancer deathThe LC treatment market ofers diverse products by companies including Amgen Inc.,Bayer AG,Boston Scientific Corp.,Innovent Biologics Inc.,and Eisai Co.LtdMultiple ongoing Phase III trials by Akeso Inc.and Astellas Pharma Inc.demonstra

3、te continued eforts to enhance LC treatment through antibody and small molecule therapiesThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or

4、 other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materi

5、als or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?Asia had the

6、highest incidence cases and accounted for nearly 70%of the global incidence cases of LCEurope had the second highest incidence,with over 88,000 casesNorth-America had more than 48,000 cases,followed by rest of the world(ROW)TRIAL CONTRIBUTIONSLIVER CANCER(LC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)55%A